ThromboGenics’ Microplasmin Phase III Program Progressing According To Schedule

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its lead product microplasmin, which is in Phase III trials for the treatment of vitreomacular adhesion, is progressing according to schedule. All protocol-specified, interim masked analyses by the independent Data Monitoring Committee (DMC) have been completed.

More: continued here

Filed under: Clinical Trials on June 27th, 2009